iBio Announces Pricing of $3.5 Million Underwritten Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Source: globenewswire
Updated: Dec 06 20220mins
IBIO.A
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on IBIO
Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 4.67 USD with a low forecast of 2.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.280
Low
2.00
Averages
4.67
High
6.00
Current: 1.280
Low
2.00
Averages
4.67
High
6.00
Oppenheimer
Jay Olson
Outperform
maintain
$5 -> $6
2025-10-30
Reason
Oppenheimer
Jay Olson
Price Target
$5 -> $6
2025-10-30
maintain
Outperform
Reason
Oppenheimer analyst Jay Olson raised the firm's price target on iBio to $6 from $5 and keeps an Outperform rating on the shares. The firm notes shares were up 8% vs. flat XBI, basking in well-deserved attention for IBIO-610 following updates from WVE's INHBE-targeting siRNA WVE-007. In its Phase 1 INLIGHT trial, WVE-007 elicited up to about 85% activin E reduction, surpassing the preclinical 70% activin E reduction threshold for potential 6-month weight loss comparable to semaglutide.
Oppenheimer
Oppenheimer
Outperform
maintain
$5 -> $6
2025-10-29
Reason
Oppenheimer
Oppenheimer
Price Target
$5 -> $6
2025-10-29
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on iBio (IBIO) to $6 from $5 and keeps an Outperform rating on the shares, calling attention for IBIO-610 following updates from Wave Life Sciences' (WVE) WVE-007 "well-deserved." Wave's initial Phase 1 INLIGHT efficacy and safety readout this quarter could provide mechanistic validation for iBio's '601 and drive additional upside, the analyst tells investors.
Oppenheimer
Outperform
initiated
$5
2025-10-20
Reason
Oppenheimer
Price Target
$5
2025-10-20
initiated
Outperform
Reason
Oppenheimer initiated coverage of iBio with an Outperform rating and $5 price target, citing "optimism" for lead asset IBIO-610 to address key challenges in treating the growing obesity market. Preclinical data validate the potential of '610 to drive both fat loss and lean mass preservation, supporting "a highly differentiated and complementary profile," says the analyst, who views the drug as "an under-the-radar" next-generations approach that "could command strategic interest."
Leerink
Roanna Ruiz
Outperform
initiated
$2
2025-10-17
Reason
Leerink
Roanna Ruiz
Price Target
$2
2025-10-17
initiated
Outperform
Reason
Leerink analyst Roanna Ruiz initiated coverage of iBio with an Outperform rating and $2 price target. The firm argues that lead obesity asset IBIO-610 represents a preclinically validated, first-in-class antibody opportunity that could address the safety and durability limitations of RNA-based competitors. Following the recent $50M public offering, iBio should maintain liquidity through all pre-IND and IND catalysts, with Series G and H warrants providing up to an additional $50M in contingent capital tied to IND milestones, Leerink adds. This structure should support a self-funding runway through the second half of 2026, aligning with the expected IND filings for IBIO-610 and IBIO-600 by year-end 2026. Further, the firm believes iBio's proprietary AI/ML-driven antibody discovery and engineering platform should provide enhanced scalability and speed to identify and optimize novel biologics.
See All Ratings
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?